Crossmark

Baseline characteristics and comparability of older multimorbid patients with polypharmacy and general practitioners participating in a randomized controlled primary care trial

Crossref DOI link: https://doi.org/10.1186/s12875-021-01488-8

Published Online: 2021-06-22

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jungo, Katharina Tabea

Meier, Rahel

Valeri, Fabio

Schwab, Nathalie

Schneider, Claudio

Reeve, Emily

Spruit, Marco

Schwenkglenks, Matthias

Rodondi, Nicolas

Streit, Sven
License Information

Text and Data Mining valid from 2021-06-22

Version of Record valid from 2021-06-22
More Information

Article History

Received: 12 January 2021

Accepted: 9 June 2021

First Online: 22 June 2021

Declarations

:

: The ethics committee of the canton of Bern (Switzerland) and the Swiss regulatory authority (Swissmedic) approved the study protocol of the OPTCIA trial and other documentation on study conduct (BASEC ID: 2018–00914). The ethics committee and Swissmedic receive annual safety reports and information about study stops/end and protocol amendments, as per local requirements. Written informed consent was obtained from all study participants participating in the OPTICA trial. The OPTICA trial was performed in accordance with relevant guidelines and regulations. The local Ethics Committee of the Canton of Zurich approved studies within the FIRE project database (BASEC-Nr. Req-2017–00797). Due to the anonymized nature of the EHR data in the FIRE database individual patient consent was not required. The analyses presented in this manuscript did not require an additional ethical approval.

: Not applicable.

: The authors do not have any conflicts of interest to declare.

Document is current

Any future updates will be listed below